Rush allergen specific immunotherapy protocol in feline atopic dermatitis: a pilot study of four cats.
Rush immunotherapy has been shown to be as safe as conventional immunotherapy in canine atopic patients. Rush immunotherapy has not been reported in the feline atopic patient. The purpose of this pilot study was to determine a safe protocol for rush immunotherapy in feline atopic patients. Four atopic cats diagnosed by history, physical examination and exclusion of appropriate differential diagnoses were included in the study. Allergens were identified via liquid phase immunoenzymatic testing (VARL: Veterinary Allergy Reference Labs, Pasadena, CA). Cats were premedicated with 1.5 mg triamcinolone orally 24 and 2 h prior to first injection and 10 mg hydroxyzine PO 24, 12 and 2 h prior to first injection. An intravenous catheter was placed prior to first injection. Allergen extracts (Greer Laboratories, Lenoir, North Carolina) were all administered subcutaneously at increasing protein nitrogen units (pnu) every 30 minutes for 5 h to maintenance dose of 15,000 pnus ml-1. Vital signs were assessed every 15 minutes. Two cats developed mild pruritus and the subsequent injection was delayed 30 minutes. No changes in either cat's vital signs were noted, nor was there any further pruritus. All four cats successfully completed rush immunotherapy. Two cats developed a dermal swelling on the dorsal neck one week later. In these four cats, this protocol appeared to be a safe regimen to reach maintenance therapy. A larger sample of feline patients is needed to determine the incidence of adverse reactions and to follow the success of ASIT based upon this method of induction.
Trimmer
Ann M
AM
Animal Dermatology Clinic, San Diego, California, USA. amtrimmer@aol.com
Griffin
Craig E
CE
Boord
Mona J
MJ
Rosenkrantz
Wayne S
WS
D000485:Allergens / Q000008:administration & dosage / Q000276:immunology*; D000818:Animals; D002371:Cat Diseases / Q000473:pathology / Q000628:therapy*; D002415:Cats; D003876:Dermatitis, Atopic / Q000628:therapy / Q000662:veterinary*; D003888:Desensitization, Immunologic / Q000662:veterinary*; D005260:Female; D007279:Injections, Subcutaneous / Q000662:veterinary; D008297:Male; D010865:Pilot Projects; D016896:Treatment Outcome
D000485:Allergens